The invasive, mesenchymal phenotype of CD44 posCD24 neg breast cancer cells has made them a promising target for eliminating the metastatic capacity of primary tumors. It has been previously demonstrated that CD44 neg/lowCD24 pos breast cancer cells lack the ability to give rise to their invasive CD44 posCD24 neg counterpart. Here we demonstrate that noninvasive, epithelial-like CD44 posCD24 pos cells readily give rise to invasive, mesenchymal CD44 posCD24 neg progeny in vivo and in vitro. This interconversion was found to be dependent upon Activin/Nodal signaling.
Breast cancer cell lines were sorted into CD44 posCD24 pos and CD44 posCD24 neg populations to evaluate their progeny for the expression of CD44, CD24, and markers of a mesenchymal phenotype. The populations, separated by fluorescence activated cell sorting (FACS) were injected into immunocompromised mice to evaluate their tumorigenicity and invasiveness of the resulting xenografts.
CD24 expression was dynamically regulated in vitro in all evaluated breast cancer cell lines. Furthermore, a single noninvasive, epithelial-like CD44 posCD24 pos cell had the ability to give rise to invasive, mesenchymal CD44 posCD24 neg progeny. Importantly, this interconversion occurred in vivo as CD44 posCD24 pos cells gave rise to xenografts with locally invasive borders as seen in xenografts initiated with CD44 posCD24 neg cells. Lastly, the ability of CD44 posCD24 pos cells to give rise to mesenchymal progeny, and vice versa, was blocked upon ablation of Activin/Nodal signaling.
Our data demonstrate that the invasive, mesenchymal CD44 posCD24 neg phenotype is under dynamic control in breast cancer cell lines both in vitro and in vivo. Furthermore, our observations suggest that therapies targeting CD44 posCD24 neg tumor cells may have limited success in preventing primary tumor metastasis unless Activin/Nodal signaling is arrested.